Health score, price, valuation, risk signals, and key metrics at a glance.
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Cash & Earnings Quality (24/25); weakest: Balance Sheet & Red Flags (8/25).
Today's multiple positioned against its own trailing range — a visual premium/discount check.
Currently below its 16-quarter median.
Currently below its 16-quarter median.
Data-driven signals worth keeping an eye on across the last 8 quarters
Revenue declined in 6 of the last 7 quarters — persistent contraction signals a fundamental problem.
as of June 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
